1. Adelaide Research & Scholarship

Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-7 of 7 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2011OCT-1 as a determinant of response to antileukemic treatmentEngler, J.; Hughes, T.; White, D.
2012BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementBranford, S.; Yeung, D.; Prime, J.; Choi, S.; Bang, J.; Park, J.; Kim, D.; Ross, D.; Hughes, T.
2011Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after Imatinib resistance is predictive of outcome during subsequent therapyParker, W.; Lawrence, R.; Ho, M.; Irwin, D.; Scott, H.; Hughes, T.; Branford, S.
2012Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileParker, W.; Ho, M.; Scott, H.; Hughes, T.; Branford, S.
2011SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaEsposito, N.; Colavita, I.; Quintarelli, C.; Sica, A.; Peluso, A.; Luciano, L.; Picardi, M.; Vecchio, L.; Buonomo, T.; Hughes, T.; White, D.; Radich, J.; Russo, D.; Branford, S.; Saglio, G.; Vaz de Melo, J.; Martinelli, R.; Ruoppolo, M.; Kalebic, T.; Martinelli, G.; et al.
2012Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemiaYeung, D.; Hughes, T.
2017CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressorsHughes, A.; Clarson, J.; Tang, C.; Vidovic, L.; White, D.; Hughes, T.; Yong, A.

Discover